Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 2
1995 4
1996 3
1997 7
1998 3
1999 3
2000 4
2001 11
2002 12
2003 11
2004 51
2005 66
2006 68
2007 89
2008 58
2009 44
2010 48
2011 42
2012 53
2013 38
2014 26
2015 28
2016 22
2017 20
2018 12
2019 11
2020 8
2021 2
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 18487514

631 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
Satow A, Maehara S, Ise S, Hikichi H, Fukushima M, Suzuki G, Kimura T, Tanak T, Ito S, Kawamoto H, Ohta H. Satow A, et al. J Pharmacol Exp Ther. 2008 Aug;326(2):577-86. doi: 10.1124/jpet.108.138107. Epub 2008 May 16. J Pharmacol Exp Ther. 2008. PMID: 18487514
Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC).
Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, Sakai N, Maehara S, Kawagoe-Takaki H, Hata M, Azuma T, Ito S, Kawamoto H, Ohta H. Suzuki G, et al. J Pharmacol Exp Ther. 2007 Jun;321(3):1144-53. doi: 10.1124/jpet.106.116574. Epub 2007 Mar 14. J Pharmacol Exp Ther. 2007. PMID: 17360958
Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one.
Satow A, Suzuki G, Maehara S, Hikichi H, Murai T, Murai T, Kawagoe-Takaki H, Hata M, Ito S, Ozaki S, Kawamoto H, Ohta H. Satow A, et al. J Pharmacol Exp Ther. 2009 Jul;330(1):179-90. doi: 10.1124/jpet.109.151118. Epub 2009 Apr 9. J Pharmacol Exp Ther. 2009. PMID: 19359526
A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.
Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, Jacobson MA, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL Jr. Kinney GG, et al. J Pharmacol Exp Ther. 2005 Apr;313(1):199-206. doi: 10.1124/jpet.104.079244. Epub 2004 Dec 17. J Pharmacol Exp Ther. 2005. PMID: 15608073
Effects of a novel metabotropic glutamate receptor 7 negative allosteric modulator, 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazonolo[4,5-c]pyridin-4(5H)-one (MMPIP), on the central nervous system in rodents.
Hikichi H, Murai T, Okuda S, Maehara S, Satow A, Ise S, Nishino M, Suzuki G, Takehana H, Hata M, Ohta H. Hikichi H, et al. Eur J Pharmacol. 2010 Aug 10;639(1-3):106-14. doi: 10.1016/j.ejphar.2009.08.047. Epub 2010 Apr 2. Eur J Pharmacol. 2010. PMID: 20371227
631 results